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Abstract
Background—Medication nonadherence and depressive symptoms predict hospitalization and
death in patients with heart failure (HF). Depressed patients have lower medication adherence than
non-depressed patients. However, the predictive power of the combination of medication
adherence and depressive symptoms for hospitalization and death has not been investigated in
patients with HF.
Objective—To explore the combined influence of medication adherence and depressive
symptoms for prediction of cardiac event-free survival in patients with HF.
Method—We monitored medication adherence in 216 HF patients who completed the Patient
Health Questionnaire-9 (PHQ-9) at baseline. Medication adherence was measured objectively
using Medication Event Monitoring System (MEMS). Patients were followed for up to 3 1/2 years
to collect data on cardiac event(s). Survival analyses were used to compare cardiac event-free
survival between/among groups.
Results—The risk of experiencing a cardiac event for patients with medication nonadherence
and depressive symptoms was 5 times higher compared to those who were medication adherent
without depressive symptoms. The risk of experiencing a cardiac event for patients with only one
risk factor was 1.2–1.3 times that of those with neither risk factor.
Conclusion—Medication nonadherence and depressive symptoms had a negative synergistic
effect on cardiac event-free survival in patients with HF.
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Introduction
Heart failure (HF) is a chronic syndrome with high incidence and prevalence, and high rates
of morbidity and mortality.1 In a meta-analysis, Rutledge and associates reported that more
than one fifth (21.5%) of patients with HF suffer from clinically significant depression 2 that
adversely affects health-related outcomes (e.g., more hospitalizations and death).2, 3
Emergency department (ED) visits, hospitalizations and death are higher in HF patients with
depressive symptoms compared to those without depressive symptoms.2, 3, 4 Specifically,
patients with HF and depressive symptoms have twice the risk of ED visits and a 29%
increase in health care costs compared to those without depressive symptoms.2 Faris and
colleagues3 examined a cohort of 396 patients with HF and also found that clinically
depressed patients were three times more likely to die compared to non-depressed patients.
Medication nonadherence 4–10, 16 also has been shown to independently predict worse
event-free survival and higher rates of ED visits, hospitalizations, and death in patients with
HF. However, medication adherence rates in this population are low, between 40–60%.11, 12
Patients with depressive symptoms are more likely to be nonadherent to their prescribed
medication than those without depressive symptoms.13 The power of the combination of
medication adherence and depressive symptoms for prediction of cardiac event-free survival
has not been previously investigated in patients with HF. Accordingly, the purpose of this
study was to explore the predictive power of the combination of medication adherence and
depressive symptoms for cardiac event-free survival in patients with HF.
Methods
Study Design
This was a secondary data analysis of two prospective studies in which patients with HF
were enrolled to measure medication adherence (measured objectively using the Medication
Event Monitoring System [MEMS]) and cardiac event-free survival.10, 14 Both studies used
identical inclusion and exclusion criteria. The first study tested the mediating effects of
nonadherence on the association between depression and HF patient outcomes. The second
study was a randomized controlled trial to determine the effect of an intervention on
morbidity and mortality outcomes. In this data analysis, we examined the relationships
among medication adherence, depressive symptoms, and cardiac event-free survival in
patients with HF.
Samples and Setting
Detailed eligibility criteria and recruitment methods have been published
previously.11, 14, 15, 21 Briefly, patients were recruited from both outpatient cardiology
clinics and inpatient cardiology units. Patients with and without systolic dysfunction were
included if they had a confirmed diagnosis of chronic HF and were prescribed the same dose
of HF medications for at least 3 months. Patients who had obvious cognitive impairment or
a co-existing terminal illness were excluded.
Measurement of Variables
Medication adherence—Medication adherence was assessed daily for 1–3 months (3
months for the first study and 1 month for the second study) using the MEMS (AARDEX®-
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USA, Union City, CA). The MEMS registered the date and time of cap openings. From the
MEMS data, medication adherence was calculated from number of days the correct number
of doses were taken during the monitoring period /total days during the monitoring period *
100%.16 Patients who took the correct number of doses on at least 88% of days were defined
as medication adherent, while all others were as nonadherent. This cutpoint was chosen
based on a study demonstrating that adherence at or above 88% predicted better event-free
survival.11
Depressive symptoms—Depressive symptoms were measured using the Patient Health
Questionnaire-9 (PHQ-9).17, 18 The PHQ-9 consists of nine items on a scale rated from 0
(not at all) to 3 (nearly every day). The instrument is scored by adding the item ratings. Total
scores of the PHQ-9 can range from 0 to 27; higher scores indicate worse depressive
symptoms. Patients who score 10 or greater are considered to have clinically significant
depressive symptoms (positive for mild to severe depression).17 The PHQ-9 is a reliable 17
and valid 17, 18 scale that has been used to measure depressive symptoms in patients with
HF.18 Internal consistency of the PHQ-9 in this study had a Cronbach’s alpha of .83.
Cardiac event-free survival—The outcome variable was the composite end-point of
time to the first cardiac event, whether it was a cardiac-related emergency department visit,
hospitalization, or death. Data on cardiac events were collected monthly by patient phone
calls, hospital record review, and review of death certificates.
Variables of interest—The following sociodemographic, clinical, and psychological data
were collected to completely describe the sample, compare differences in characteristics by
groups, and obtain data on potential confounding variables.
Sociodemographics: Age, gender, marital status, ethnicity, and education level were
collected from patient interview.
Clinical variables: New York Heart Association (NYHA) functional class was assessed by
patient interview.19 Left ventricular ejection fraction (LVEF), etiology of HF, and
prescribed medications were collected from the medical record and patient interview.
Psychological variable: Anxiety was assessed using the Brief Symptom Inventory (BSI)
anxiety subscale.20 The anxiety subscale of the BSI consists of six items. Patients were
asked to rate their level of distress on a scale from 0 (not at all) to 4 (extremely). The scores
of the 6 items are summed and averaged for a total score that can range from 0 to 4; higher
scores indicate a greater level of anxiety. The anxiety subscale of the BSI is a reliable
(Cronbach’s α = .87)20 and valid scale that has been used to measure anxiety in patients
with HF21 and myocardial infarction.20 For this sample, the Cronbach’s α was .84.
Procedure
This study was approved by the appropriate Institutional Review Board. All patients
provided informed, signed consent. Patients’ sociodemographic and clinical characteristics,
anxiety, and depressive symptoms were collected by interview and medical record review at
baseline. After completion of the baseline assessment, patients were given instructions on
use of the MEMS bottle. Patients started to use the MEMS bottle from baseline. They
returned the MEMS bottle after one or three months of continuous use of the MEMS device.
Patients or family members were contacted monthly by phone to collect outcome data.
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Data Management and Analysis
All data analyses were performed using SPSS (Chicago, IL), version 17.0; a significance
level of .05 was chosen to indicate statistical significance. An evidence-based cutpoint of
88% medication adherence rate by the MEMS11 was used to categorize patients into
adherent and nonadherent groups. Patients were divided into presence or absence depressive
symptoms groups based on the cutpoint score of 10 on the PHQ-9. We examined differences
between medication adherent and nonadherent and between presence or absence depressive
symptoms groups using independent t-tests and chi-square tests. Patients were further
divided into 4 groups: (1) medication adherent without depressive symptoms; (2) medication
adherent with depressive symptoms; (3) medication nonadherent without depressive
symptoms; and (4) medication nonadherent with depressive symptoms. We used one way
analysis of variance (ANOVA) with the Least Significant Difference (LSD) post hoc tests
and Pearson chi-square tests to evaluate differences among the 4 groups.
The Kaplan-Meier and log-rank test was used to compare the time to cardiac event-free
survival: (1) between patients in the adherent and nonadherent groups; (2) in the presence or
absence of depressive symptoms; and (3) among adherent without depressive symptoms,
adherent with depressive symptoms, nonadherent without depressive symptoms, and
nonadherent with depressive symptoms groups. Cox proportional hazards regression
modeling was used to assess the time to cardiac event-free survival between adherent and
nonadherent groups, between presence or absence depressive symptoms groups, and among
these four groups with and without adjusting for the following potential confounding
variables: age, NYHA functional class, angiotensin converting enzyme inhibitor (ACEI) use,
and anxiety (these variables were different among groups, please see Table 2). To account
for differences between the two studies, we also controlled for study group (i.e., study 1 or




A total of 216 patients with HF who had complete PHQ-9 and MEMS data were included in
the analysis. The mean age of patients in the sample was 60 ± 12 years, about one third of
patients were female. The majority of the patients were Caucasian (85%) and married
(62%). Full sample characteristics and comparison of medication adherent vs. nonadherent
groups and presence or absence depressive symptoms are presented in Table 1.
Medication adherence
Of the total sample, 88 out of the 216 patients were classified as nonadherent to prescribed
HF medication. As shown in the Table 1, patients in the medication nonadherent group had
more depressive symptoms (p = .018) and higher anxiety scores (p = .009) than those in the
adherent group.
Depressive symptoms
The mean of the PHQ-9 was 6.3 (standard deviation = 5.5). More than one quarter (26%) of
the patients in this study had depressive symptoms. Patients with depressive symptoms were
younger (p = .003), had higher percentage of patients with NYHA III/IV (p < .001), higher
anxiety scores (p < .001), and were more commonly medication nonadherent (p = .018), and
fewer were taking ACEI (p = .016) (Table 1) than patients without depressive symptoms.
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Medication adherence and depressive symptoms
When we compared the characteristics of the 4 patient groups stratified by medication
adherence and depressive symptoms, there were differences in NYHA class, ACEI use, and
anxiety among groups (Table 2). Patients who were medication adherent without depressive
symptoms were older compared with those who were medication nonadherent with
depressive symptoms (p = .022). More patients who were medication nonadherent with
depressive symptoms were prescribed an ACEI compared with the other groups. Regardless
of medication adherence, more patients with depressive symptoms were in NYHA Class III
or IV and had higher levels of anxiety than patients with no depressive symptoms.
Association of medication adherence with cardiac event-free survival
The time to the first cardiac event was significantly shorter in nonadherent patients than in
adherent patients (p = .005, Figure 1). In simple Cox regression modeling (Table 3),
medication adherence predicted cardiac event-free survival (hazard ration [HR] =2.1). After
controlling for study group, group assignment, age, NYHA functional class, ACEI use, and
anxiety, patients who were medication nonadherent still had 1.8 times the risk of
experiencing a cardiac event compared to patients who were adherent (Table 3).
Association of depressive symptoms with cardiac event-free survival
The composite endpoint of cardiac event-free survival was significantly shorter in patients
with depressive symptoms than those without depressive symptoms (p < .001, Figure 2).
Depressive symptoms predicted cardiac event-free survival before and after controlling for
covariates. Patients with depressive symptoms had more than twice the risk of experiencing
a cardiac event compared to patients without depressive symptoms (Table 3).
Combined Effect of Medication Adherence and Depressive Symptoms on Cardiac Event-
free Survival
Of the total sample, 103 (47%) patients were classified as medication adherent without
depressive symptoms, 25 (12%) were medication adherent with depressive symptoms, 58
(27%) were medication nonadherent without depressive symptoms, and 30 (14%) were
medication nonadherent with depressive symptoms. In the Kaplan-Meier and log-rank test,
the composite endpoint of cardiac event-free survival was significantly worse in patients
who were nonadherent with depressive symptoms than in other groups (chi-square = 29.7, p
< .001). In the Cox regression, patients who were nonadherent with depressive symptoms
experienced the shortest cardiac event-free survival of all the other groups (p < .001).
Patients who were nonadherent with depressive symptoms had a 5 times higher risk of a
cardiac event than those who were adherent without depressive symptoms (p < .001). In the
Kaplan-Meier and log-rank test, the composite endpoint of cardiac event-free survival was
significantly worse in NYHA III/IV patients than those with NYHA I/II (chi-square = 4.238,
p = 0.04). When adding study group, group assignment, age, NYHA functional class, ACEI
use, and anxiety to the model, patients who were nonadherent with depressive symptoms
had a 5.2 times higher risk of cardiac events than patients who were adherent without
depressive symptoms (Table 4). NYHA class was no longer a significant predictor of
cardiac event-free survival in the multiple Cox regression. Patients who were nonadherent
without depressive symptoms or those who were adherent with depressive symptoms had a
1.2–1.3 times higher risk of a cardiac event than those who were adherent without
depressive symptoms before and after controlling for covariates (Table 4).
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This is the first study to explore the prediction of cardiac event-free survival from the
combination of medication adherence and depressive symptoms in patients with HF. We
found that medication adherence and depressive symptoms independently predicted cardiac
event-free survival in patients with HF. Consistent with prior investigators’ findings, HF
patients who were adherent to prescribed medications had a lower risk of cardiac events than
those who were nonadherent.10, 11 Likewise, HF patients who had depressive symptoms had
a higher risk of ED visits, hospitalizations, or death than those who had no depressive
symptoms.2, 3
The most striking finding from this study was that medication adherence and depressive
symptoms in combination predicted cardiac event-free survival in patients with HF in a
synergistic fashion. In the Cox regression model, when HF patients were divided into 4
groups stratified by medication adherence and depressive symptoms, the risk of
experiencing a cardiac event for patients with both risk factors (medication nonadherence
and depressive symptoms) was 5 times compared to those who were medication adherent
without depressive symptoms before and after adjusting for covariates; while the risk of
experiencing a cardiac event for patients with only one risk factor was 1.3 times that of those
with neither risk factor.
We identified three studies in which both medication adherence and depressive symptoms
predicted health outcomes.22–24 Morgan and colleagues 22, 50 found that difficulty taking
medications, an aspect of medication nonadherence, and depressive symptoms in patients
with HF were independent predictors of worse health status scores on the Kansas City
Cardiomyopathy Questionnaire. In a recent prospective study in 107 heart transplantation
recipients, Favaro and associates 24 investigated the role of major depression and medication
adherence in the prediction of outcomes from cardiac transplantation and found that
presence of an episode of major depression prior to cardiac transplantation indirectly
predicted mortality through post-transplant malignancies, while poor medication adherence
was a significant predictor of mortality. In a sample of 111 patients with HF, Moser and
colleagues23 examined whether nonadherence mediated the relationship between depression
and outcomes and found that medication adherence but not dietary sodium adherence
mediated the link between depression and rehospitalization/mortality. Our findings were
consistent with these prior investigators’ findings that both medication nonadherence and
depressive symptoms predicted poor outcomes. However, the combined effect of medication
adherence and depressive symptoms was not examined in these studies. Our study advances
our understanding of this relationship by demonstrating that medication nonadherence and
depressive symptoms in combination, predicted worse cardiac event-free survival in patients
with HF before and after controlling for some important covariates. Therefore, clinicians
should take both medication adherence and depressive symptoms seriously, screen/assess
regularly, and should strive to provide appropriate intervention/treatment when needed.
It is well-documented that depressive symptoms predict shorter cardiac event-free
survival.2, 3, 25–29, 4, 23, 24, 25, 26 Patients with depressive symptoms were more likely to have
ED visits,25 hospital readmissions,25, 26, 28 and death26, 27 compared with those without
depressive symptoms.24, 25 There are several mechanisms that could be related to the
association between depressive symptoms and increased risk for ED visits, hospitalization,
or death. Patients with depressive symptoms have lower heart rate variability,30, 31 a higher
inflammatory response,32 hyperactivity of sympathetic nervous system, greater severity of
HF,29 higher platelet activity, and more frequent myocardial ischemia which may explain, in
part, worse outcomes.33 In the current HF literature, NYHA classification has been found to
be related to depressive symptoms34–36 and survival37, 38 in patients with HF, and also been
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used to assess HF severity.39, 40 In our study, patients with depressive symptoms were more
likely to have advanced HF as reflected by NYHA functional class compared with those
without depressive symptoms. In the Kaplan-Meier and log-rank test, patients with NYHA
III/IV had shorter cardiac event-free survival than those with NYHA I/II. This result is
consistent with prior studies showing the impact of NYHA on rehospitalization or mortality
in HF.37, 38 However, when we adjusted NYHA class in the Cox regression, NYHA class
was not a predictor of cardiac event-free survival, suggesting that the observed relationship
among medication adherence, depressive symptoms, and outcomes was not a result of
confounding. However, we cannot rule out the possibility of unmeasured confounders (e.g.,
inflammatory markers) in this observational study.
In addition to these physiologic factors, medication adherence is one of the most common
explanations linking depression and worse outcomes.3, 25, 27 Investigators have suggested
that worse outcomes of patients with depressive symptoms might be associated with reduced
adherence to medical therapy.3, 25, 27 In our study, more patients with depressive symptoms
were medication nonadherent than without depressive symptoms. Our result was consistent
with most prior studies that depression was associated with medication nonadherence.41–48
Many studies have focused on why depressed patients are more likely to be nonadherent
than non-depressed patients. Investigators have suggested the reasons for patients with
depressive symptoms are more likely to be nonadherent to their treatment regimen might
due to greater feelings of hopelessness, being socially isolated, withdrawal from social
network, possible reductions in the cognitive functioning that may affect memory, and no
energy to carry out medical regimen.27, 49 In a sample of 280 patients with HF, excessive
daytime sleepiness and mild cognitive decline were 2.5 times more likely to be medication
nonadherent than those without excessive daytime sleepiness or cognitive decline.50
However, we did not examine these variables in our study. Therefore, more research is
needed to explore the linkages between depressive symptoms and medication adherence.
When we compared sociodemographic, clinical, and psychological variables among 4
groups (stratified by medication adherence and depressive symptoms), age, NYHA
functional class, ACEI use, functional status, and anxiety were different among groups.
Patients with medication nonadherent and depressive symptoms group were younger, were
more likely to be NYHA III/IV class, were less likely to use ACEI, had worse functional
status, and had a higher level of anxiety than those in other groups. However, when we
adjusted for age, NYHA class, ACEI use, and anxiety in the Cox regression model, patients
with medication nonadherence and depressive symptoms still had the highest risk of
experiencing a cardiac event, suggesting that the predictive power of the combination of
depressive symptoms and medication adherence for cardiac event-free survival was robust.
Limitations
Participants were recruited from one Southern tertiary hospital. Our sample included 85%
Caucasian, 65% male, and 62% married patients. Therefore, our findings warrant further
study to confirm these results in a more diverse sample of patients with HF.
Second, we have small sample size within some of the 4 adherence/depression groups.
Future studies of this phenomenon should include a larger number of each group, especially
for medication adherent/nonadherent patients with depressive symptoms so that the complex
dynamics surrounding depressive symptoms, medication adherence and outcomes can be
better illuminated. Thus our findings should be considered exploratory and the need for
replication emphasized.
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Third, we assessed HF severity using NYHA class instead of a more objective marker such
as natriuretic peptides. However, investigators have shown plasma brain natriuretic peptide
(BNP) levels were significantly increased in accordance with the NYHA class.51 And even
the measure of natriuretic peptide has limitations with regard to its ability to accurately
reflect severity of heart failure. For example, extreme values of plasma BNP do not correlate
with the presence of HF or cardiomyopathy, thus limiting the usefulness of BNP as a marker
of HF severity.52
Finally, medication adherence might be inflated by using the MEMS because patients knew
their medication-taking behaviors were monitored (i.e., Hawthorne effect). However, the
MEMS is considered a “gold standard” measure to assess medication adherence in the
current adherence literature and is the closest way to get to actual behavior.53 From prior
validation studies of the MEMS, serum blood levels were correlated with MEMS data
indicating that patients take their medication when they open the MEMS caps and further
studies have demonstrated that there was no Hawthorne effect with the use of the MEMS.54
Conclusion
The major finding of this study was that medication adherence and depressive symptoms
combined to produce a synergistic effect in the prediction of cardiac event-free survival. The
study highlights the importance of medication adherence and patient’s depressive symptoms.
Interventions to improve clinical outcomes should address both medication adherence and
depressive symptoms.
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Depressive symptoms and cardiac event-free survival
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Cardiac event-free survival for patients stratified by medication adherence and depressive
symptoms.
A: Medication adherent without depressive symptoms
B: Medication adherent with depressive symptoms
C: Medication nonadherent without depressive symptoms
D: Medication nonadherent with depressive symptoms
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Table 3
Cox regression modeling: medication adherence alone and depressive symptoms alone on Cardiac Event-free
Survival (N = 216)
Variables Hazard Ratio 95% CI p
Simple Cox Regression: without adjusting
Medication adherence*
Medication adherent 1.0 - -
Medication nonadherent 2.07 1.242–3.462 .005
Depressive symptoms**
No depressive symptoms 1.0 - -
Depressive symptoms 2.65 1.568–4.489 < .001
Cox Regression: adjusting for covariates†
Medication adherence‡
Medication adherent 1.0 - -
Medication nonadherent 1.80 1.065–3.042 .028
Depressive symptoms§
No depressive symptoms 1.0 - -
Depressive symptoms 2.404 1.255–4.606 .008
CI: confidence interval
*
chi-square = 8.117; p = .004;
**
chi-square = 14.278; p < .001
†
Controlling for study group, group assignment, age, New York Heart Association functional class, and angiotensin-converting-enzyme inhibitor
use.
‡
chi-square = 19.187; p = .008
§
chi-square = 22.02; p = .003
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Table 4
Cox regression modeling: combined effects of medication adherence and depressive symptoms on Cardiac
Event-free Survival (N = 216)
Variables Hazard Ratio 95% CI p
Simple Cox Regression: without adjusting*
Medication adherent without depressive symptoms 1.0 - -
Medication adherent with depressive symptoms 1.41 .568–3.5 .46
Medication nonadherent without depressive symptoms 1.366 .704–2.652 .14
Medication nonadherent with depressive symptoms 4.949 2.6–9.423 < .001
Cox Regression: adjusting for covariates**
Step 1
  Study group 1.447 .752–2.786 .27
  Group assignment 2.577 1.085–6.119 .03
Step 2
  Age 1.003 .980–1.026 .82
  NYHA 1.291 .863–1.932 .21
  ACEI use .757 .429–1.334 .34
  Anxiety 1.412 1.003–1.988 .048
Step 3
  Medication adherent and no depressive symptoms 1.0 - -
  Medication adherent and depressive symptoms 1.302 .492–3.445 .60
  Medication nonadherent and no depressive symptoms 1.227 .625–2.407 .55
  Medication nonadherent and depressive symptoms 5.175 2.318–11.551 < .001
CI: confidence interval
*
chi-square = 30.537, p < .001
**
chi-square = 37.818, p < .001
NYHA=New York Heart Association functional class, ACEI=angiotensin-converting-enzyme inhibitor.
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